RNANasdaqPharmaceutical PreparationsFiscal year ends December 31
Atrium Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$7.61−0.06 (-0.78%)
Close on Oct 19, 2026
- Market cap
- $130.18M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
90.6%
15M of 17M shares
Institutional holders
155
40 new, 46 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| John Petry | 1,500,000 | 8.80% | 13G (passive) | Jun 30, 2026 |
| T. Rowe Price Associates, Inc. | 1,472,984 | 8.60% | 13G (passive) amendment | Jun 30, 2026 |
| BlackRock, Inc. | 1,135,757 | 6.60% | 13G (passive) amendment | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of RNA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Sessa Capital IM, L.P. | 1,500,000 | 8.77% | $20.18M | +948,609 | 0.34% |
| Price T Rowe Associates Inc /Md/ | 1,472,984 | 8.61% | $19.81K | −80,226 | 0.00% |
| BlackRock, Inc. | 1,447,476 | 8.46% | $19.47M | +242,185 | 0.00% |
| Crcm LP | 1,283,078 | 7.50% | $17.26M | New | 5.68% |
| Vanguard Capital Management LLC | 730,831 | 4.27% | $9.83M | +103,962 | 0.00% |
| TIG Advisors, LLC | 561,533 | 3.28% | $7.55M | −46,019 | 0.33% |
| Arbiter Partners Capital Management LLC | 522,576 | 3.05% | $7.03M | +292,576 | 1.85% |
| Cantor Fitzgerald, L. P. | 513,834 | 3.00% | $6.91M | +278,197 | 0.04% |
| Geode Capital Management, LLC | 386,929 | 2.26% | $5.21M | +67,098 | 0.00% |
| Two Sigma Investments, LP | 345,481 | 2.02% | $4.65M | +166,921 | 0.00% |
| Goldman Sachs Group Inc | 310,341 | 1.81% | $4.17M | −39,609 | 0.00% |
| 683 Capital Management, LLC | 300,000 | 1.75% | $4.04M | – | 0.20% |
| State Street Corp | 271,762 | 1.59% | $3.66M | +14,676 | 0.00% |
| Slotnik Capital, LLC | 237,637 | 1.39% | $3.20M | +56,692 | 0.83% |
| Weiss Asset Management LP | 219,730 | 1.28% | $2.96M | −20,971 | 0.03% |
| Millennium Management LLC | 200,559 | 1.17% | $2.70M | +9,700 | 0.00% |
| Schonfeld Strategic Advisors LLC | 199,158 | 1.16% | $2.68M | +36,399 | 0.01% |
| Aqr Capital Management LLC | 172,235 | 1.01% | $2.32M | New | 0.00% |
| Nexpoint Asset Management, L.P. | 150,025 | 0.88% | $2.02M | – | 0.13% |
| Polar Asset Management Partners Inc. | 150,000 | 0.88% | $2.02M | +80,000 | 0.03% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 155 | 15M | 90.6% | 40 / 47 | 35 / 46 | 5M | 4M |
| Q1 2026 | 163 | 15M | 86.7% | 163 / 0 | 0 / 0 | 15M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of RNA | Value | % of fund | As of |
|---|---|---|---|---|---|
| T. Rowe Price Health Sciences Fund, Inc. | 566,428 | 3.31% | $7.62M | 0.06% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 518,416 | 3.03% | $6.97M | 0.00% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 443,263 | 2.59% | $5.96M | 0.04% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 377,354 | 2.21% | $5.08M | 0.01% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 188,626 | 1.10% | $2.54M | 0.00% | Jun 30, 2026 |
| BlackRock Event Driven Equity Fund | 175,388 | 1.03% | $2.28M | 0.05% | May 29, 2026 |
| Fidelity Small Cap Index Fund | 154,179 | 0.90% | $1.75M | 0.01% | Jul 31, 2026 |
| Nexpoint Merger Arbitrage Fund | 135,138 | 0.79% | $1.82M | 0.12% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 88,107 | 0.52% | $1.19M | 0.01% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 73,533 | 0.43% | $955.93K | 0.00% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 67,639 | 0.40% | $879.31K | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 62,889 | 0.37% | $817.56K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 48,184 | 0.28% | $648.07K | 0.04% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Portfolio | 41,700 | 0.24% | $560.87K | 0.07% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 41,090 | 0.24% | $552.66K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Kathleen P. Gallagher | See Remarks, Director | 119,729 | 0.70% | Sep 22, 2026 |
| Husam Younis | Chief Scientific Officer | 41,441 | 0.24% | Sep 22, 2026 |
| Steven George Hughes | Chief Medical Officer | 51,638 | 0.30% | Sep 22, 2026 |
| Brendan R. Winslow | Chief Financial Officer | 36,859 | 0.22% | Sep 22, 2026 |
| Stephanie Kenney | See Remarks | 33,085 | 0.19% | Sep 22, 2026 |
| Rocio Martin Hoyos | Chief Strategy Officer | 38,340 | 0.22% | Sep 22, 2026 |
| W. Michael Flanagan | Director | 31,974 | 0.19% | Sep 22, 2026 |
| Sarah Boyce | Director | 138,668 | 0.81% | Sep 22, 2026 |
| Carsten Boess | Director | 11,005 | 0.06% | Mar 2, 2026 |
| Simona Skerjanec | Director | 5,902 | 0.03% | Mar 2, 2026 |
| Troy Edward Wilson | Director | 11,731 | 0.07% | Mar 2, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Steven George Hughes Chief Medical Officer | Sep 18, 2026 | Tax withholding | −21,459 | $8.95 | $192.06K | 51,638 |
| Stephanie Kenney See Remarks | Sep 18, 2026 | Tax withholding | −2,375 | $8.95 | $21.26K | 33,085 |
| Brendan R. Winslow Chief Financial Officer | Sep 18, 2026 | Tax withholding | −6,742 | $8.95 | $60.34K | 36,859 |
| Rocio Martin Hoyos Chief Strategy Officer | Sep 18, 2026 | Tax withholding | −8,320 | $8.95 | $74.46K | 38,340 |
| Sarah Boyce Director | Sep 18, 2026 | Tax withholding | −126,418 | $8.95 | $1.13M | 138,668 |
| Kathleen P. Gallagher See Remarks, Director | Sep 18, 2026 | Tax withholding | −11,632 | $8.95 | $104.11K | 119,729 |
| Husam Younis Chief Scientific Officer | Sep 18, 2026 | Tax withholding | −11,216 | $8.95 | $100.38K | 41,441 |
| W. Michael Flanagan Director | Sep 18, 2026 | Tax withholding | −22,812 | $8.95 | $204.17K | 31,974 |
| Husam Younis Chief Scientific Officer | Apr 20, 2026 | Award | +30,000 | – | – | 52,657 |
| Steven George Hughes Chief Medical Officer | Apr 20, 2026 | Award | +30,000 | – | – | 73,097 |
| Rocio Martin Hoyos Chief Strategy Officer | Apr 20, 2026 | Award | +30,000 | – | – | 46,660 |
| Kathleen P. Gallagher See Remarks, Director | Apr 20, 2026 | Award | +102,500 | – | – | 131,361 |
| Brendan R. Winslow Chief Financial Officer | Apr 20, 2026 | Award | +30,000 | – | – | 43,601 |
| Stephanie Kenney See Remarks | Apr 20, 2026 | Award | +30,000 | – | – | 35,460 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.